Dr. Dia points out 2 key areas for ongoing process improvement. First, he emphasizes the need to consider the use of ACE inhibitor therapy for all patients with known CAD. "Based on the results of the HOPE Trial, we know that patients with CAD have a mortality benefit from the use of ACE even before their first event."
Secondly, Dr. Dia recommends getting a lipid profile even if the ideal 24-hour window is missed for AMI patients. "If the LDL value is normal or elevated after the first 24 hours post-MI; it was even higher before! More importantly, the Heart Protection Study suggests the important role of statin therapy in stabilizing plaque and decreasing the inflammatory process in Acute Coronary Syndrome regardless of the LDL value.